Drug, bio-affecting and body treating compositions inventions 10/09

20090247450 - G-csf liquid formulation: The invention relates to G-CSF liquid formulations that have a long shelf-life and to methods for producing the same. The invention also relates to liquid formulations containing G-CSF as the active substance, acetate as the buffer substance, polysorbate 20 or polysorbate 80 as the surfactant and optionally pharmaceutically acceptable adjuvants,... Agent: Knobbe Martens Olson & Bear LLP

20090247451 - Therapeutic compositions for age-related macular degeneration: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.... Agent: Townsend And Townsend And Crew, LLP

20090247452 - Pharmaceutical formulations for reducing pain: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically... Agent: Howrey LLP-ca

20090247453 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090247456 - Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy: The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.... Agent: Jones Day

20090247458 - Compositions and methods for treating cystic fibrosis: Particular aspects provide electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with... Agent: Davis Wright Tremaine, LLP/seattle

20090247462 - Fgf variants and methods for use thereof: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment... Agent: Winston & Strawn LLP Patent Department

20090247460 - Inhibitor of vascular endothelial cell growth factor: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth... Agent: Merck And Co., Inc

20090247455 - Isolation of inhibitors of ires-mediated translation: The present invention relates to a method for identifying or determining a compound that inhibits or reduces internal ribosome entry site (IRES) mediated translation. For example, the present invention provides a method for determining a compound that inhibits IRES-mediated translation, said method comprising expressing in a cell a counter selectable... Agent: Fenwick & West LLP

20090247454 - Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease: Methods and kits for detecting a predisposition to develop gestational diabetes mellitus and pharmacological treatment for this disease.... Agent: Berenbaum, Weinshienk & Eason, P.c

20090247461 - Methods for therapeutic treatment of pain: A medicament for therapeutic and/or prophylactic treatment of pain such as neuropathic pain that occurs after peripheral or central nerve injury, which contains ginsenoside Rb1 as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20090247459 - Modified recombinant factor viii and von willebrand factor and methods of use: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present... Agent: Baxter Healthcare Corporation

20090247457 - Neurotrophic components of the adnf i complex: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing... Agent: Townsend And Townsend And Crew, LLP

20090247463 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20090247464 - Compositions and methods for topical application and transdermal delivery of an oligopeptide: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably... Agent: King & Spalding

20090247465 - Novel use of bivalirudin in the treatment of acute coronary syndrome: A method of treating acute coronary syndrome (ACS) in a patient, comprising administering a therapeutically effective amount of an indirect thrombin inhibitor to the patient, and subsequently administering a therapeutically effective amount of a direct thrombin inhibitor to the patient wherein the direct thrombin inhibitor is administered prior to and... Agent: Gibbons P.c.

20090247466 - Neuroprotective integrin-binding peptide and angiopoietin-1 treatments: The present invention provides therapeutic compositions, kits and methods for treating nervous system injury in a mammal. Certain methods include administering to a mammal in need of such therapy an effective amount of angiopoietin-1 (Ang-1), or a functional analog thereof. Certain methods include administering a peptide having 4 to 20... Agent: Viksnins Harris & Padys Pllp

20090247467 - Peptide epitopes of vegfr-2/kdr that inhibit angiogenesis: The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.... Agent: Klarquist Sparkman, LLP

20090247468 - Pharmaceutical compositions: Methods of spray drying are described.... Agent: Vertex Pharmaceuticals Inc.

20090247474 - 3-aminopyrrolidine derivatives as modulators of chemokine receptors: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The... Agent: Fish & Richardson Pc

20090247473 - Acythiols and component thiol compositions as anti-hiv and anti-retroviral agents: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of... Agent: Townsend And Townsend And Crew, LLP

20090247471 - Inhibitors of cruzipain and other cysteine proteases: r

20090247469 - Ophthalmic compositions comprising a dipeptide: An ophthalmic composition comprising one or more antimicrobial components and a dipeptide. The dipeptide comprises a glycine moiety and another amino acid moiety other than glycine. The ophthalmic compositions include contact lens care solutions for cleaning and disinfecting contact lenses.... Agent: Bausch & Lomb Incorporated

20090247470 - Phenylalanine dipeptide derivatives, compositions and use thereof: Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the smae, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat... Agent: Darby & Darby P.c.

20090247472 - Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents: This invention relates to compounds with the formula (I) given below or one of their pharmaceutically acceptable salts, as a medicine; Formula (I) of pharmaceutical compositions comprising one or more compounds with Formula (I) as active constituent, use of compounds with Formula (I) for the preparation of compositions designed to... Agent: Bachman & Lapointe, P.c.

20090247476 - Mannitol and/or proline for prevention and treatment of ageing related symptoms: The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol 5 and/or proline containing compositions that are particularly useful for the treatment of premature ageing related symptoms in mammalian subjects suffering from genetic defects in DNA damage response... Agent: Swanson & Bratschun, L.l.c.

20090247475 - Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies: The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs.... Agent: Fulbright & Jaworski L.l.p.

20090247477 - Methods of suppressing uv light-induced skin carcinogenesis: Administration of the isothiocyanate protects against UV light-induced skin carcinogenesis. In particular, topical application or dietary administration of isothiocyanate sulforaphane after exposure to UV radiation provides effective protection against skin tumor formation. Sulforaphane analogs and glucosinolates also can be employed. Lotions useful for suppressing UV light-induced skin carcinogenesis also are... Agent: Foley And Lardner LLP Suite 500

20090247478 - Novel macrolides and ketolides having antimicrobial activity: The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-γ lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods... Agent: Bio Intellectual Property Services (bio Ips) Llc

20090247479 - Therapeutic use of methionine to reduce the toxicity of aminoglycoside antibiotics: Methods of preventing or reducing ototoxicity in patients undergoing treatment with therapeutically effective amounts of aminoglycoside antibiotics are provided. The methods comprise administering an effective amount of an otoprotective agent comprising methionine or a methionine-like moiety to said patient prior to, simultaneously with, or subsequently to administration of the aminoglycoside... Agent: Siu School Of Medicine Office Of Technology Transfer

20090247480 - Anti-cancer therapies: Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20090247481 - Compositions and kits for treating influenza: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.... Agent: Adamas Pharmaceuticals, Inc.

20090247482 - 50 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090247607 - Dsrna compositions and methods for treating hpv infection: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of... Agent: Novartis Corporate Intellectual Property

20090247610 - Integrase cofactor: The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.... Agent: Clark & Elbing LLP

20090247611 - Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel: Provided is a method of treating cancer of the stomach, comprising administering to a patient a therapeutically effective combination of a Survivin antisense oligonucleotide and paclitaxel.... Agent: Eli Lilly & Company

20090247606 - Rna interference mediated inhibition of adenosine a1 receptor (adora1) gene expression using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating adenosine A1 receptor (ADORA1) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against ADORA1... Agent: Sirna Therapeutics, Inc.

20090247604 - Rnai therapeutics for treatment of eye neovascularization diseases: Compositions and methods for treating ocular disease are provided. Specifically, siRNA molecules and mixtures of siRNA molecules are provided that inhibit angiogenesis and/or neovascularization. The compositions and methods are suitable for treating ocular diseases associated with angiogenesis and/or neovascularization.... Agent: Ropes & Gray LLP

20090247609 - Sm-protein based secretion engineering: The present invention concerns the field of cell culture technology. It describes a novel method for enhancing the secretory transport of proteins in eukaryotic cells by heterologous expression of Munc18c, Sly1 or other members of the SM protein family. This method is particularly useful for the generation of optimized host... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090247608 - Targeting lipids: where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that... Agent: Lando & Anastasi, LLP

20090247605 - Treating diseases mediated by metalloprotease-shed proteins: This invention relates to the identification of membrane-associated proteins shed by metalloproteinases and in particular by TNF-alpha converting enzyme (TACE), to the use of such metalloproteinase-shed proteins in assays for TACE agonists and antagonists, and to the use of metalloproteinase agonists and antagonists, and particularly TACE agonists and antagonists, in... Agent: Immunex Corporation Law Department

20090247614 - Folate conjugates: i

20090247612 - Prevention of viral infectivity: The present invention concerns the inactivation of viral infectivity in a cell-free environment as well as the preparation of a pharmaceutical agent and a method therefore. According to the invention the use of a sequence of oligodeoxynucleotides or oligoribonucleotides or a chimera or a combination thereof capable of binding to... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20090247613 - Rna interference mediated inhibition of b-cell cll/lymphoma-2 (bcl2) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating BCL2 gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BCL2 gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090247615 - Triggered rnai: The present application relates to methods and compositions for triggering RNAi. Triggered RNAi is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, methods of silencing or modulating the expression of a target gene are provided. The methods generally comprise providing an initiator to... Agent: Knobbe Martens Olson & Bear LLP

20090247483 - Method for treatment of macular degeneration: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090247484 - Compounds: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090247485 - Barrier film-forming compositions and methods of use: Long-lasting persistent, uniform, film-forming skin protecting compositions provide long-lasting persistent barrier films when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis and as wound care agents. A barrier film-forming agent is selected from pullulan, pullulan derivatives and combinations thereof. The barrier... Agent: Lathrop & Gage LLP

20090247486 - Composition for oral substance coating, covering material for oral substance, edible container and oral substance using the same: A composition for oral substance coating, a covering material for an oral substance or an edible container, includes an indigestible and water-insoluble dietary fiber derived from a plant, alga or fungus, or a hemicellulose or protopectin, and an oral substance uses the same.... Agent: Birch Stewart Kolasch & Birch

20090247487 - Combination therapy to treat hepatitis b virus: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering... Agent: King & Spalding

20090247488 - Anti-inflammatory phosphonate compounds: The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090247489 - Dihydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Brinks Hofer Gilson & Lione

20090247490 - Topical compositions containing phosphorylated polyphenols: The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning... Agent: The Estee Lauder Cos, Inc

20090247491 - Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof: The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavouring agent; and purified water; a process for preparing a composition according to the present invention; and use of... Agent: Patent Central Llc Stephan A. Pendorf

20090247492 - Manganese based organometallic complexes, pharmaceutical compositions and dietetic products: The invention relates to compounds and their uses, particularly in the pharmaceutical and dietetic industries. The invention discloses complexes having Mn-SOD like activities, as well as methods for treating various diseases associated with oxidative stress, including cancer and inflammatory conditions, by administering said compounds. It further deals with pharmaceutical compositions... Agent: Nixon & Vanderhye, Pc

20090247493 - Regimens for treatment of conditions related to estrogen deficiency: The present invention relates to methods of stimulating estrogen production that can be used to treat peri-menopausal or estrogen deficiency conditions utilizing regimens involving administration of estrogen and progestin, followed by a hormone-free period.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090247494 - Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders: I have developed a unique pharmaceutical composition containing Omega-3 essential fatty acids and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as fissures and ulcers, hemorrhoids, pruritis ani, and colon-rectal disorders such as procto-sigmoiditis by topical application to or... Agent: Phillip Kofsky

20090247495 - Cucurbitacin b and uses thereof: The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a... Agent: Wilkinson & Grist

20090247496 - Pharmaceutical composition and extract of poria for enhancing uptake of nutrients: e

20090247497 - Formulation and use of ergosta-7,22-dien-3beta-ol: An isolated and purified form of ergosta-7,22-dien-3β-ol and its use as a marker for identifying Coriolus versicolor (Yunzhi) are provided. A composition used for treatment of cancer and other related diseases or disorders comprising ergosta-7,22-dien-3β-ol is also provided.... Agent: Eagle Ip Limited

20090247498 - Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications: Compositions having an effective amount of an antibacterial agent may be useful in the treatment of amyotrophic lateral sclerosis (ALS) and other diseases of the nervous system. The compositions may include an extraordinary amount of an antibacterial agent. Ceftriaxone has stopped the progression of ALS for a second time after... Agent: Haugen Law Firm

20090247499 - Sulfonylated piperazines as cannabinoid-1 receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20090247501 - Protein kinase inhibitors: Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds... Agent: Woodcock Washburn LLP

20090247502 - Substituted pyridoxazines: and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3 and R4 are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20090247503 - 5-demethoxyfumagillol and derivatives thereof: Provided herein are 5-demethoxyfumagillol and its derivatives. Also provided herein are methods of making the 5-demethoxyfumagillol and derivatives. Also provided herein are biological activities of the 5-demethoxyfumagillol and derivatives and methods of using same for treating diseases.... Agent: Jones Day

20090247500 - Novel compounds as cannabinoid receptor ligands: o

20090247504 - Indazole derivatives for treatment of alzheimer's disease: Compounds of formula (IA) and (IB) are inhibitors of MARK, and hence are suitable for treatment of Alzheimer's disease.... Agent: Merck And Co., Inc

20090247505 - Spiro(5.5)undecane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247506 - Antibacterial agents: e

20090247508 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090247507 - Enzyme inhibitors: Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent... Agent: Banner & Witcoff, Ltd.

20090247509 - Novel heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247510 - Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension: The present invention relates to the use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension or pulmonary hypertension.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247511 - Synergistic insecticide and fungicide mixtures: e

20090247512 - Macrocylic inhibitors of hepatitis c virus:

20090247513 - Benzothiophene compounds having antiinfective activity:

20090247514 - Spirolactam aryl cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, A5, A6, A7, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The... Agent: Merck And Co., Inc

20090247515 - 11 beta-hsd1 modulators: h

20090247516 - 3- (benzo [d] [1,3] dioxol-5-ylmethyl) -4- (thio) oxo-2- (thio) oxo-azolidin-5-ylidene derivatives as antibacterial agents: The present invention concerns novel azolidine compounds of Formula (I) wherein X denotes S, NH, CH2 or O, Y and W denotes each independently S or O, Q denotes CH or N, n and m are an integer from 0 to 2, and R1 and R2 denote independently from each... Agent: Manelli Denison & Selter

20090247518 - 6-(2-alkyl-phenyl)-pyrido[2,3-d]pyrimidines useful as protein kinase inhibitors: e

20090247517 - Compounds and compositions as inhibitors of cannabinoid receptor 1 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).... Agent: Novartis Corporate Intellectual Property

20090247519 - Amino-ethyl-amino-aryl (aeaa) compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions,... Agent: Michael Best & Friedrich LLP

20090247520 - Inhibitors of antigen receptor-induced nf-kappa b activation: A method to identify selective inhibitors of antigen receptor-mediated NF-κB activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors.... Agent: Techlaw LLP 10755 Scripps Poway Parkway

20090247522 - Hsp90 family protein inhibitors: (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or... Agent: Fitzpatrick Cella Harper & Scinto

20090247521 - Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction: The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.... Agent: Foley & Lardner LLP

20090247523 - Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.... Agent: Philip S. Johnson Johnson & Johnson

20090247524 - Hsp90 inhibitor: Compounds represented by formula (1) shown below, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such compounds are provided.... Agent: Fish & Richardson Pc

20090247525 - Sigma receptor inhibitors: m

20090247526 - Glucokinase activators: wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG... Agent: Viksnins Harris & Padys Pllp

20090247527 - Substituted gamma lactams as therapeutic agents: e

20090247528 - Method of treating attention deficit disorder: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about... Agent: Pfizer Inc. Patent Department

20090247529 - Topical compositions: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present... Agent: Dr. Reddy''s Laboratories, Inc.

20090247530 - Substituted 4-aminocyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247531 - Crystalline forms of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester: Crystalline form, Form N-1, of [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising the Form N-1 of Compound I as well as a method of using the Form N-1 of Compound I in the treatment of cancer and... Agent: Louis J. Wille Bristol-myers Squibb Company

20090247532 - Crystalline polymorph of sitagliptin phosphate and its preparation: The present invention is directed to a novel polymorph form of crystalline sitagliptin phosphate, named as Form V herein. The present invention further provides processes for preparations of Form V, pharmaceutical composition comprising Form V and its use in therapy. Form V can be prepared from recrystallizing sitagliptin phosphate in... Agent: Mae De Ltd.

20090247533 - Ecteinascidins: The present invention is directed to several newly discovered ecteinascidin (Et) species, designated herein as Et 731, Et 815, Et 808, and Et 594. The physical properties of these compounds, their preparation and therapeutic properties are also reported.... Agent: King & Spalding

20090247534 - New compounds: e

20090247535 - Use of ranolazine for non-cardiovascular disorders:

20090247536 - Bissulfonamide compounds as agonists of galr1, compositions, and methods of use: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20090247537 - Methods for preventing or treating bruxism using dopaminergic agents: Methods for preventing or treating bruxism, including alleviating or eliminating one or more symptoms, diseases or conditions associated with or resulting from bruxism, using dopaminergic agents such as monoamine oxidase inhibitors that increase dopaminergic activity and dopamine agonists, are disclosed.... Agent: Black Lowe & Graham, Pllc

20090247539 - Novel pharmaceuticals: This invention relates to compounds of formula (I)... Agent: Pfizer Inc. Patent Department

20090247538 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors: The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N═C(R6), (R7)C═N, (R8)N—C(O), (R8)2C—C(O), N═N or (R7)C═C(R6); E is a monocyclic carbocyclic or... Agent: Heslin Rothenberg Farley & Mesiti Pc

20090247540 - Peptide and small molecule agonists of epha and their uses: Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090247541 - Novel compounds: wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090247542 - Syntheses and preparations of polymorphs of crystalline aripiprazole: The invention relates to polymorphic crystalline forms of aripiprazole, synthetic processes for their preparation and pharmaceutical compositions containing the same. These crystalline forms of aripiprazole can be readily milled and can be easily combined with various pharmaceutical adjuvants without effecting changes to their crystalline structure when, for example, pressed into... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20090247543 - Gatifloxacin-containing aqueous liquid preparation: There is provided an aqueous liquid preparation comprising Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof, phosphoric acid or a salt thereof, and xanthan gum, wherein a pH thereof is 5.5 or more and less than 7.0. The aqueous liquid preparation has improved intraocular penetration of Gatifloxacin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090247544 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247545 - Substituted oxazolidinone derivatives: The present invention provides substituted oxazolidinone derivatives, which can be used as antimicrobial agents. Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacteria, such as, inter alia, multiply-resistant Staphylococci, Streptococci, Enterococci, Bacterioides spp., Clostridium spp., Mycobacterium spp. Bacillus spp.,... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090247546 - Treatment of prevention of valvular heart disease with flibanserin: The invention relates to a method for the treatment or prevention of Valvular Heart Disease comprising the administration of a therapeutically effective amount of flibanserin.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090247547 - Hydroxamate-based inhibitors of deacetylases b: e

20090247550 - 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as hdl-cholesterol raising agents:

20090247549 - Methods of using saha and bortezomib for treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second... Agent: Merck And Co., Inc

20090247548 - Pyrrolopyrimidine derivatives for treating proliferative diseases: e

20090247551 - Substituted enaminocarbonyl compounds: The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, Pc

20090247552 - Aqueous liquid preparation containing amide compound: e

20090247553 - Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity: Provided herein is a highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione, a process for the preparation thereof, and pharmaceutical compositions comprising highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity.... Agent: Cantor Colburn, LLP

20090247555 - 5,7-disubstituted[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives 258: wherein R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in... Agent: Pepper Hamilton LLP

20090247554 - Kinase inhibitors: Compounds are provided for use with kinases that comprise (I), (II), (III), (IV): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.... Agent: Takeda San Diego, Inc.

20090247556 - Azolopyrimidines as inhibitors of cannabinoid 1 activity: The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).... Agent: Genomics Institute Of The Novartis Research Foundation

20090247557 - Partial and full agonists of a1 adenosine receptors: e

20090247558 - Use of the crh (corticotropin releasing hormone) - ucn (urocortin) system in the treatment of inflammatory diseases: The invention relates to the use of corticotropin-releasing hormone (CRH) receptor-1 (R1) antagonists and/or CRH-R2 receptor agonists for the treatment of inflammatory diseases via regulation of monocyte/macrophage cell activation, proliferation, differentiation, apoptosis, and inflammatory cytokine production. As CRH system we define natural and synthetic CRH and urocortin (UCN) agonists and... Agent: Sughrue Mion, Pllc

20090247559 - Benzofuropyrimidinones: e

20090247560 - Diaryl ketimine derivative: [wherein R1a and R1b are the same or different, representing a hydrogen atom, etc.; R2a and R2b are the same or different, representing a hydrogen atom, etc., or R2a and R2b, taken together, form —CH2CH2—, R3a and R3b are the same or different, representing a hydrogen atom, etc.; or R3a... Agent: Merck And Co., Inc

20090247561 - Substituted spirocyclic cyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247562 - Large substituent, non-phenolic opioids and methods of use thereof: e

20090247564 - Crystalline form of vinflunine ditartrate: The present invention relates to a novel crystalline form of vinflunine, to a process for preparing it, and to its uses in the therapeutic field, in particular for treating cancer.... Agent: Birch Stewart Kolasch & Birch

20090247563 - Novel processes for the production of useful intermediates: The present application relates to a new process for the asymmetric production of 3-(pyridin-4-yl)-3-hydroxy-pentanoic acid derivatives, which are useful intermediates in the manufacture of compounds that are known to show antiproliferative activity.... Agent: Hunton & Williams LLP Intellectual Property Department

20090247567 - Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using... Agent: Viksnins Harris & Padys Pllp

20090247566 - Pyrano [3,2-c] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof: n

20090247565 - Tyrosine kinase inhibitors: The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090247568 - Aminopiperidinyl derivatives and uses thereof: e

20090247569 - Process for preparing clopidogrel bisulphate: Provided are processes for the preparation of clopidogrel bisulphate Form I.... Agent: Kenyon & Kenyon LLP

20090247571 - Certain chemical entities, compositions and methods: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247570 - Pharmaceuticals: The present invention relates to the use of a CCR5 antagonist in an HIV infected patient to enhance their immune reconstitution and so treat to HIV related opportunistic conditions resulting from the immunocompromised state of the HIV patient. The invention also allows treatment with a CCR5 antagonist of patients having... Agent: Pfizer Inc Mary J Hosley

20090247573 - (hetero)aryl cyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247574 - 3-amino-pyridine derivatives for the treatment of metabolic disorders: e

20090247572 - Agent for treating atrial fibrillation: It is intended to provide an agent for treating atrial fibrillation, comprising an If current inhibitor as an active ingredient. In the present invention, the means for resolution comprises an agent for treating atrial fibrillation, comprising an If current inhibitor as an active ingredient. In particular, it comprises an agent... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247575 - Stabilizing lipid compositions for oral pharmaceutical agents: The present invention relates to a pharmaceutical composition for oral administration comprising an exceptionally labile active agent, a stabilizing vehicle comprising liquid triglycerides and a desiccant, wherein the composition is storage stable for an extended period without substantial degradation of the active agent.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20090247578 - 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials: e

20090247576 - Anti-tumor agent for multiple myeloma: The object of the invention is to provide a pharmaceutical composition and a therapeutic method which can exert their effects with higher efficiency on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR3, a cell that has a t(4;14) translocation and... Agent: Darby & Darby P.c.

20090247577 - Pyrrolidine derivatives useful as bace inhibitors: e

20090247579 - 2-[3h-thiazol-2-ylidinemethyl]pyridines and related compounds and their use:

20090247580 - Nitroxide radioprotector formulations and methods of use: Pharmaceutical compositions useful in preventing and treating negative side effects accompanying radiotherapy are disclosed. More particularly, new formulations that can be applied to the skin and mucous membranes of patients undergoing radiotherapy and methods of using these formulations are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20090247581 - Organic compounds: The present invention relates to a process for the synthesis of (S)-2′[2-1-(methyl-2-piperidyl) ethyl] cinnamanilide (I) or salts or pharmaceutically acceptable prodrugs thereof:... Agent: Novartis Corporate Intellectual Property

20090247582 - Methods of treating atherosclerosis: e

20090247583 - Pharmaceutical composition comprising, in combination, saredutant and paroxetine: A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from trans-(−)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine and pharmaceutically acceptable salts thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247584 - Phenoxy-piperidines for the treatment of diseases such as schizophrenia and depression: Compounds of the formula (I), in which R1, R2′, R2″, R2′″, R3 and n are as defined in Claim 1, are effectors of the nicotinic and/or muscarinic acetylcholine receptor and are suitable for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases,... Agent: Millen, White, Zelano & Branigan, P.c.

20090247585 - Pharmaceutical composition comprising, in combination, saredutant and escitalopram: A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from (S)-(+)-1-[4-(3-(dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile and pharmaceutically acceptable salts thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247587 - 1,3-dihydroisobenzofuran derivatives: The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090247586 - Carboxamides for controlling micro-organisms in plant and material protection: e

20090247588 - 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents:

20090247589 - Monocarboxylates for modifying macrophage function: The present invention is directed to methods of inhibiting the production of proinflammatory agents by macrophages by contacting the cells with a monocarboxylate such as nicotinic acid. The invention also includes methods of treating diseases that are associated with macrophage activation such as atherosclerosis; systemic lupus erythematosus; rheumatoid arthritis; inflammatory... Agent: Law Office Of Michael A. Sanzo, Llc

20090247590 - Indane amides: The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090247591 - Substituted cyclohexyldiamines: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain or other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247592 - Epothilones c, d, e, and f, preparation and compositions: The present invention relates to epothilones C, D, E, and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247593 - N-thiazol-2-yl-benzamide derivatives: e

20090247594 - Therapeutic compounds:

20090247595 - Process for the preparation of tetrazolyl compounds: The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and related tetrazolyl compounds and includes a method of removing a protective group (e.g., triphenylmethane (trityl) protecting group) from an N-protected tetrazolyl compound using a Lewis... Agent: Frommer Lawrence & Haug

20090247596 - Thiophenecarboxamide derivatives as ep4 receptor ligands: The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090247597 - Agrochemical formulations that can be dispersed in water containing polyalkoxytriglycerided as penetration enhances: The present invention relates to novel water-dispersible agrochemical formulations such as, for example, water-based suspension concentrates and water-dispersible granules of agrochemically active compounds comprising a penetrant from the class of the polyalkoxytriglycerides, to a process for preparing these formulations and to their use for applying the active compounds comprised therein.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, Pc

20090247599 - Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule: There are disclosed methods and kits for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing schedules.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090247598 - Treatment methods: There are disclosed methods for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing regimen and/or schedules based on the patient's MGMT level. Additional improved methods for treating patients with temozolomide are also disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090247600 - Remedy for corneal diseases: A therapeutic agent for a corneal disease comprising ozagrel or a salt thereof as an active ingredient is provided. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090247601 - Peptide derivatives with therapeutic activity: Dipeptide compounds containing a histidine residue proved to have interesting blocking activity on secondary products from lipid oxidative stress, in particular on unsaturated aldehydes such as malondialdehyde and hydroxynonenal, which are known to contribute to the inset of quite a number of chronic pathologies such as neurodegenerative, inflammatory chronic, cardiovascular... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20090247602 - Cosmetic use of conjugated compounds of indolic auxins: p

20090247603 - Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor: The present invention is a new stable drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a surfactant, and a method for manufacturing same. When applied to unstable drugs with low solubility... Agent: Peacock Myers, P.c.

20090247616 - Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety: The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to... Agent: Philip S. Johnson Johnson & Johnson

20090247618 - Process for preparation of benzo-fused heteroaryl derivatives: The present invention is directed to processes for the preparation of benzo-fused heteroaryl derivatives, useful for the treatment of epilepsy and related disorders. The present invention is further directed to processes for the preparation of intermediates in the synthesis of the benzo-fused heteroaryl derivatives.... Agent: Philip S. Johnson Johnson & Johnson

20090247617 - Process for the preparation of benzo-fused heteroaryl sulfamates: The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090247619 - Cannabinoid-containing compositions and methods for their use: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the... Agent: Crowell & Moring LLP Intellectual Property Group

20090247620 - Benzochromene derivatives for use in liquid crystal media and as therapeutic active substances: where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in TN, OCB, LCOS and/or IPS-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as... Agent: Millen, White, Zelano & Branigan, P.c.

20090247621 - Diosmetin compounds, a process for their preparation and pharmaceutical composition containing them: e

20090247622 - Natural topical compositions for the prevention and treatment of diaper rashes and related conditions: The treatment and prevention of skin irritations, including diaper rash, is facilitated with the topical application of cranberry anthocyanins in a cosmetically acceptable vehicle.... Agent: Abelman, Frayne & Schwab

20090247623 - Derivatives of epirubicin, their medicinal application and pharmaceuticaly acceptable forms of drugs: The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.... Agent: Brooks Kushman P.c.

20090247624 - Formulations of radioprotective alpha beta unsaturated aryl sulfones: Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective α,β unsaturated aryl sulfone wherein the composition has a pH within the range of... Agent: Law Offices Of Khalilian Sira, Llc

20090247625 - Compositions containing lignan-class compounds: An object of the invention is to provide compositions containing lignan-class compounds as dissolved at high concentrations. The compositions having lignan-class compounds such as sesamin and episesamin dissolved in solvent oils or fats that contain triglycerides of middle-chain fatty acids having 8-12 carbon atoms, preferably triglycerides of caprylic acid and/or... Agent: Drinker Biddle & Reath (dc)

20090247626 - Method of treating dyslipidemia using naturally occurring diterpene: A method for treatment and or/prevention of dyslipidemia is provided. The invention relates to reducing low density lipoprotein cholesterol concentration by using naturally occurring diterpene (16α-hydroxycleroda-3,13(14)Z-dien-15,16-olide, a compound having formula (1)) isolated from leaves of Polyalthia longifolia.... Agent: Greenlee Winner And Sullivan P C

20090247627 - Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor... Agent: Theravance, Inc.

20090247628 - Substituted phenylcyclohexylglycolates: Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090247629 - Dimer poly-quaternary ester compounds: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with an alkanolamine to make an ester quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of... Agent: Kevin O'lenick

20090247632 - Dermatological compositions and methods: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.... Agent: Mueting, Raasch & Gebhardt, P.a.

20090247630 - Dermatological compositions comprising at least one naphthoic acid compound and at least one film-forming agent and treatment of keratinization disorders therewith: Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound essentially uniformly distributed therethrough and an amount of at least one hydrophilic film-forming agent, formulated into topically applicable, physiologically acceptable media therefor.... Agent: Buchanan, Ingersoll & Rooney Pc

20090247631 - Enzymatic production of peracids using perhydrolytic enzymes: A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090247634 - Methods for identifying modulators of eoxin formation: p

20090247633 - Nutrient extracts derived from green plant materials: An extract from green plant materials includes controlled concentrations of nutritional components. In one embodiment, the nutritional components include at least one xanthophyll, at least one hydrocarbon carotene, and at least one fatty acid wherein the xanthophyll, hydrocarbon carotene, and fatty acid each have about equal weight percentages. In a... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090247636 - Agent for suppression of gastric emptying comprising 4-hydroxyisoleucine: The present invention aims to provide a more effective gastric emptying suppressant and food intake suppressant, wherein the solving means are a gastric emptying suppressant containing 4-hydroxyisoleucine or a salt thereof and a food intake suppressant containing 4-hydroxyisoleucine or a salt thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090247635 - Method for treating anal pruritis and other perianal disorders: The invention relates to methods and compositions for the treatment of pruritis ani and other perianal disorders. There are currently few treatments for these conditions, many of which have significant side effects. The methods of the invention involve the administration, in a cream or lotion of pregabalin, an anti-epileptic agent... Agent: Jonathan D. Feuchtwang

20090247637 - Novel anthranilic acid derivatives: e

20090247638 - Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders:

20090247639 - Sulfonic acid and aldehyde condensation polymers for the treatment and prevention of hpv: The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof.... Agent: Foley And Lardner LLP Suite 500

20090247640 - Antimicrobials having polyquaternary ammoniums and alcohol-bearing amidoamines and methods for their use: Antimicrobial or preservative compositions with high user comfort and/or low ocular irritation. The compositions comprise a polyquaternary ammonium compound and an amidoamine having an alcohol group and exhibit synergistic antimicrobial activity. The compositions may be used as stand-alone antimicrobials/preservatives or may be incorporated into other ocular compositions such as those... Agent: Abbott Medical Optics, Inc.

20090247641 - Hydrazone agents to treat cutaneous lesions: A method is disclosed for treating hyperproliferative body surface lesions, including cancerous or precancerous lesion, such as warts or anogenital cancers, by applying a polyaryl mononitro- or dinitrophenylhydrazone such as (I) wherein R1 is hydrogen, hydroxy, 2- or 4-hydroxyphenyl, acetate, nitroso, phosphate, azido, nitrile, amino, dimethylamino, sulfate, methylsulfonate, phosphate, succinate... Agent: Dickstein Shapiro LLP

20090247642 - Synthesis and preparations of metoprolol and its salts: The invention relates to an improved process for preparing metoprolol and its salts.... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20090247643 - Medicinal herbal composition for treating infection: Herbal compositions derived from Kenyan plants are provided for the treatment of HIV and other infectious diseases. The herbal compositions can include the extracts of up to 14 plants, including the root of Dovyalis abyssinica and Clutia robusta. Also provided are methods for extracting alkaloids and other compounds from the... Agent: Cooper & Dunham, LLP

20090247644 - Memantine formulations: The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090247645 - Stabilized compositions of alkylating agents and methods of using same: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum... Agent: Gfd Patents, Llc

20090247646 - Use of resveratrol and derivatives thereof for promoting the wellness state in mammals: The invention relates to the use of resveratrol, a derivative, metabolite or analogue thereof for promoting the wellness state of a mammal or for changing gene expression profiles in older adult mammals towards conformity with expression profiles found in younger adult mammals as well as to their use for the... Agent: Nixon & Vanderhye, Pc

20090247647 - Method of stimulating proteoglycan synthesis in cells: A method of stimulating the production of proteoglycans in a living animal cell comprising administering one or more Vitamin D3 metabolites to the living cells is provided.... Agent: Nelson Mullins Riley & Scarborough, LLP

20090247648 - Sebum absorption compositions: Sebum absorption compositions are disclosed which include (a) 1% to 20% by weight of the composition of a sebum absorption ingredient; and (b) 20% to 99% by weight of the composition of a volatile solvent.... Agent: Fulbright & Jaworski L.l.p.

20090247649 - Compositions using evaporable silicone carriers for cosmetics, cleaning and care product compositions: where R1 and R2 are selected from the group of linear or branched monovalent hydrocarbon radicals having from one to eight carbon atoms and where each R3, R4, R5, R6, and R7 is independently selected from the group of monovalent hydrocarbon radicals having from one to sixty carbon atoms; and... Agent: Dilworth & Barrese, LLP

20090247650 - Novel cationic associative polyurethanes and their use as thickeners: e

20090247651 - Bioadhesive composition formed using click chemistry: The present disclosure provides compositions which may be utilized as adhesives or sealants in medical and surgical applications. The compositions may, in embodiments, be formed from the cycloaddition reaction of a first component possessing at least one azide group with a second component possessing at least one alkyne group.... Agent: Tyco Healthcare Group Lp